Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antibiotic + microbial transplantation therapy
- Development stage
- Unknown
- Lead developer
- Rima Rachid
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Antibiotic + microbial transplantation therapy is an investigational treatment protocol for peanut allergy. The regimen consists of a 7-day pretreatment with oral antibiotics to clear the patient's existing gut microbiome, followed by a 28-day course of oral encapsulated Microbial Transplantation Therapy (MTT). MTT is a purified and concentrated form of fecal microbiota transplant (FMT) containing less than 1% fecal material, composed of live bacteria from healthy, non-allergic donors. The therapy aims to restore healthy bacterial populations in the gut that promote immune tolerance and increase the threshold of peanut reactivity. It is currently being evaluated in Phase II clinical trials led by Dr. Rima Rachid at Boston Children's Hospital in collaboration with the University of Minnesota.
- Other names
- oral encapsulated microbiota transplantation therapymicrobial transplantation therapyfecal microbiota transplant
Beyond the preview
Go deeper on antibiotic + microbial transplantation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antibiotic + microbial transplantation therapy.